Progyny, Inc. (NASDAQ:PGNY) CEO Peter Anevski Sells 32,000 Shares

Posted by Defense World Staff on May 17th, 2023

Progyny, Inc. (NASDAQ:PGNY – Get Rating) CEO Peter Anevski sold 32,000 shares of the stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $36.24, for a total transaction of $1,159,680.00. Following the completion of the sale, the chief executive officer now owns 215,924 shares of the company’s stock, valued at approximately $7,825,085.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Peter Anevski also recently made the following trade(s):

On Friday, May 12th, Peter Anevski sold 32,000 shares of Progyny stock. The shares were sold at an average price of $36.30, for a total transaction of $1,161,600.00.
On Wednesday, May 10th, Peter Anevski sold 32,000 shares of Progyny stock. The shares were sold at an average price of $37.74, for a total transaction of $1,207,680.00.
On Monday, May 8th, Peter Anevski sold 22,932 shares of Progyny stock. The shares were sold at an average price of $35.09, for a total transaction of $804,683.88.
On Monday, April 24th, Peter Anevski sold 1,857 shares of Progyny stock. The shares were sold at an average price of $35.00, for a total transaction of $64,995.00.
On Friday, April 21st, Peter Anevski sold 8,370 shares of Progyny stock. The shares were sold at an average price of $35.01, for a total transaction of $293,033.70.
On Thursday, March 2nd, Peter Anevski sold 32,000 shares of Progyny stock. The shares were sold at an average price of $36.12, for a total transaction of $1,155,840.00.

Progyny Stock Performance

NASDAQ PGNY opened at $35.95 on Wednesday. The company has a market capitalization of $3.39 billion, a PE ratio of 83.60, a price-to-earnings-growth ratio of 2.13 and a beta of 1.51. The company has a 50-day simple moving average of $33.34 and a 200 day simple moving average of $33.67. Progyny, Inc. has a 52-week low of $25.67 and a 52-week high of $46.50.

Progyny (NASDAQ:PGNY – Get Rating) last posted its earnings results on Monday, May 8th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.10. The firm had revenue of $258.40 million during the quarter, compared to the consensus estimate of $246.63 million. Progyny had a net margin of 4.93% and a return on equity of 11.81%. The company’s revenue was up 50.1% on a year-over-year basis. During the same quarter last year, the company earned $0.05 earnings per share. As a group, analysts forecast that Progyny, Inc. will post 0.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Progyny

Large investors have recently modified their holdings of the business. Arizona State Retirement System increased its stake in shares of Progyny by 2.0% in the third quarter. Arizona State Retirement System now owns 19,989 shares of the company’s stock worth $741,000 after purchasing an additional 384 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of Progyny in the third quarter worth about $1,020,000. Envestnet Asset Management Inc. boosted its position in shares of Progyny by 45.0% in the fourth quarter. Envestnet Asset Management Inc. now owns 174,963 shares of the company’s stock valued at $5,450,000 after acquiring an additional 54,258 shares during the period. Bessemer Group Inc. boosted its position in shares of Progyny by 7.3% in the third quarter. Bessemer Group Inc. now owns 92,195 shares of the company’s stock valued at $3,416,000 after acquiring an additional 6,258 shares during the period. Finally, Barclays PLC boosted its position in shares of Progyny by 321.4% in the third quarter. Barclays PLC now owns 15,819 shares of the company’s stock valued at $586,000 after acquiring an additional 12,065 shares during the period. Hedge funds and other institutional investors own 86.12% of the company’s stock.

Wall Street Analysts Forecast Growth

PGNY has been the subject of a number of research analyst reports. Bank of America raised their price objective on shares of Progyny from $48.00 to $50.00 in a report on Tuesday, May 9th. Cantor Fitzgerald raised their price objective on shares of Progyny from $44.00 to $45.00 in a report on Tuesday, May 9th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $48.67.

Progyny Company Profile

(Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.